0001127602-12-009009.txt : 20120301
0001127602-12-009009.hdr.sgml : 20120301
20120301181629
ACCESSION NUMBER: 0001127602-12-009009
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20120228
FILED AS OF DATE: 20120301
DATE AS OF CHANGE: 20120301
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: ALLOS THERAPEUTICS INC
CENTRAL INDEX KEY: 0001097264
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 541655029
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 11080 CIRCLEPOINT ROAD
STREET 2: SUITE 200
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
BUSINESS PHONE: 3034266262
MAIL ADDRESS:
STREET 1: 11080 CIRCLEPOINT ROAD
STREET 2: SUITE 200
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: BENNETT BRUCE K JR
CENTRAL INDEX KEY: 0001237532
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-29815
FILM NUMBER: 12659454
MAIL ADDRESS:
STREET 1: 11080 CIRCLE POINT RD., STE. 200
CITY: WESTMINSTER
STATE: CO
ZIP: 80020
4
1
form4.xml
PRIMARY DOCUMENT
X0304
4
2012-02-28
0001097264
ALLOS THERAPEUTICS INC
ALTH
0001237532
BENNETT BRUCE K JR
11080 CIRCLEPOINT ROAD
SUITE 200
WESTMINSTER
CO
80020
1
VP, Pharmaceutical Operations
Common Stock
2012-02-28
4
A
0
43862
0
A
153434
D
Common Stock
2012-02-29
4
S
0
3031
1.5252
D
150403
D
Common Stock
2012-03-01
4
S
0
3025
1.495
D
147378
D
Represents shares of common stock issued as restricted stock units ("RSUs") awarded under the Company's 2008 Equity Incentive Plan (the "Plan"). The RSUs shall vest in a series of eight (8) successive equal semi-annual installments over the four (4)-year period measured from March 18, 2012 (the "Vesting Commencement Date"), subject to Participant's Continuous Service through each such date.
These shares are being sold pursuant to a 10b5-1 plan for Mr. Bennett under which a portion of his holdings were sold for tax and estate planning purposes in connection with the delivery of shares covered by restricted stock units which vested on February 28, 2012.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.52 to $1.54. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
The price represents the weighted average sale price for multiple transactions reported on this line. The prices of the transactions ranged from $1.49 to $1.50. Upon request of the SEC staff, Allos Therapeutics, Inc. (the "Company") or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold at each separate price.
/s/ David C. Clark, attorney-in-fact for Bruce K. Bennett Jr.
2012-03-01